Total Payments
$14,299
2024 Payments
$35.12
Companies
14
Transactions
36
Medicare Patients
2,171
Medicare Billing
$331,270
Payment Breakdown by Category
Consulting$5,733 (40.1%)
Travel$4,617 (32.3%)
Other$2,000 (14.0%)
Food & Beverage$1,548 (10.8%)
Education$400.58 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,733 | 2 | 40.1% |
| Travel and Lodging | $4,617 | 5 | 32.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000 | 1 | 14.0% |
| Food and Beverage | $1,548 | 21 | 10.8% |
| Education | $400.58 | 7 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $5,846 | 3 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $4,813 | 10 | $0 (2017) |
| Rigel Pharmaceuticals, Inc. | $2,092 | 3 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $390.59 | 6 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $239.08 | 4 | $0 (2020) |
| Genentech USA, Inc. | $198.09 | 2 | $0 (2022) |
| Heron Therapeutics, Inc. | $137.20 | 1 | $0 (2018) |
| Seattle Genetics, Inc. | $124.03 | 1 | $0 (2018) |
| Kite Pharma, Inc. | $121.85 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $111.82 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35.12 | 1 | Mirati Therapeutics, Inc. ($35.12) |
| 2022 | $284.84 | 4 | Genentech USA, Inc. ($198.09) |
| 2021 | $291.65 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($291.65) |
| 2020 | $153.65 | 4 | E.R. Squibb & Sons, L.L.C. ($141.20) |
| 2019 | $2,214 | 4 | Rigel Pharmaceuticals, Inc. ($2,092) |
| 2018 | $6,232 | 7 | Celgene Corporation ($5,846) |
| 2017 | $5,087 | 13 | Bayer HealthCare Pharmaceuticals Inc. ($4,813) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/10/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $35.12 | General |
| Category: Oncology | ||||||
| 11/07/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $78.73 | General |
| 05/10/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $119.36 | General |
| 04/06/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $67.95 | General |
| 04/01/2022 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $91.67 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $99.99 | General |
| 07/23/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $99.99 | General |
| 11/18/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 08/25/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $10.60 | General |
| Category: Oncology | ||||||
| 07/15/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $10.60 | General |
| Category: Oncology | ||||||
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $120.00 | General |
| 08/21/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Hematology | ||||||
| 08/10/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Hematology | ||||||
| 08/10/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $42.30 | General |
| Category: Hematology | ||||||
| 02/28/2019 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $121.85 | General |
| Category: ONC | ||||||
| 10/11/2018 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $3,850.00 | General |
| 10/11/2018 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,732.50 | General |
| 10/01/2018 | Celgene Corporation | — | Travel and Lodging | In-kind items and services | $263.96 | General |
| 08/15/2018 | Heron Therapeutics, Inc. | SUSTOL (Drug) | Food and Beverage | In-kind items and services | $137.20 | General |
| Category: CINV | ||||||
| 06/12/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $124.03 | General |
| Category: Oncology | ||||||
| 04/26/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $111.82 | General |
| Category: Oncology | ||||||
| 04/03/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: Oncology | ||||||
| 12/08/2017 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/08/2017 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Travel and Lodging | In-kind items and services | $212.06 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 535 | 990 | $322,360 | $92,890 |
| 2022 | 10 | 556 | 1,021 | $290,916 | $87,645 |
| 2021 | 9 | 471 | 910 | $220,060 | $79,597 |
| 2020 | 10 | 609 | 1,043 | $234,921 | $71,138 |
Total Patients
2,171
Total Services
3,964
Medicare Billing
$331,270
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 107 | 328 | $128,936 | $37,073 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 207 | 417 | $115,755 | $30,641 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 64 | 64 | $30,720 | $9,001 | 29.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 47 | 56 | $23,190 | $7,887 | 34.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 25 | $5,275 | $2,502 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 20 | 20 | $7,260 | $2,226 | 30.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 25 | $3,675 | $1,663 | 45.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 24 | $4,728 | $1,110 | 23.5% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 29 | 31 | $2,821 | $788.40 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 216 | 555 | $147,740 | $41,997 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 74 | 164 | $62,450 | $19,277 | 30.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 57 | 57 | $26,645 | $8,129 | 30.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 50 | 52 | $21,424 | $7,955 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 22 | 22 | $7,946 | $2,352 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 41 | 44 | $8,245 | $2,144 | 26.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 47 | 60 | $5,460 | $1,719 | 31.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 27 | $3,969 | $1,534 | 38.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 17 | $3,587 | $1,466 | 40.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 19 | 23 | $3,450 | $1,071 | 31.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 171 | 538 | $119,436 | $42,361 | 35.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 71 | 106 | $31,588 | $12,136 | 38.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 57 | 57 | $24,225 | $8,642 | 35.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 39 | 44 | $18,128 | $7,402 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 63 | 79 | $11,850 | $3,892 | 32.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 18 | 18 | $6,174 | $2,069 | 33.5% |
About Dr. Abhishek Kalla, M.D
Dr. Abhishek Kalla, M.D is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1508085887.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abhishek Kalla, M.D has received a total of $14,299 in payments from pharmaceutical and medical device companies, with $35.12 received in 2024. These payments were reported across 36 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($5,733).
As a Medicare-enrolled provider, Kalla has provided services to 2,171 Medicare beneficiaries, totaling 3,964 services with total Medicare billing of $331,270. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 04/24/2007
- Last Updated 04/25/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1508085887
Products in Payments
- Non-Covered $4,813
- Tavalisse (Drug) $2,092
- SUSTOL (Drug) $137.20
- ADCETRIS (Biological) $124.03
- NINLARO (Drug) $122.66
- Yescarta (Drug) $121.85
- IMBRUVICA (Drug) $111.82
- EMPLICITI (Biological) $97.88
- KRAZATI (Drug) $35.12
- OPDIVO (Biological) $21.20
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816